Acadia Pharmaceuticals Inc (ACAD): R&D Expense
$328.80M
Year ended 2025-12-31
$331.01M
Trailing 12 months to 2026-06-30
-3.1%
3-year compound annual growth
+0.6%
5-year compound annual growth
+16.1%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $328.80M | +8.4% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $303.25M | -13.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $351.62M | -2.8% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $361.57M | +51.0% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $239.41M | -25.0% | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $319.13M | +32.8% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $240.38M | +28.4% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $187.16M | +25.5% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $149.19M | +50.3% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $99.28M | +34.4% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $73.87M | +21.9% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $60.60M | +126.8% | 2017-02-28, From 2014-01-01 |
| 2013-12-31 | $26.72M | +42.2% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $18.79M | +8.6% | 2015-02-26, From 2012-01-01 |
| 2011-12-31 | $17.31M | -15.9% | 2014-02-27, From 2011-01-01 |
| 2010-12-31 | $20.58M | -50.5% | 2013-03-12, From 2010-01-01 |
| 2009-12-31 | $41.59M | n/a | 2012-03-06, From 2009-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $328.80M | +8.4% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2025-12-31 | $388.52M | +64.1% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $915.62M | +1.6% |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $97.00M | -9.3% |
| ANI Pharmaceuticals Inc (ANIP) | 2025-12-31 | $51.66M | +15.9% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $189.59M | +30.0% |
| Arrowhead Pharmaceuticals, Inc. (ARWR) | 2025-09-30 | $607.16M | +20.0% |
| Collegium Pharmaceutical, Inc (COLL) | 2024-12-31 | $0 | n/a |
| Alkermes plc. (ALKS) | 2025-12-31 | $323.96M | +32.1% |
Compare ACAD, MDGL, IONS, INDV side by side · Screen every company in Pharmaceutical Preparations ↗